PropThink

About the Author PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically complicated companies and equities that are grossly over- or under-valued. We offer regular market coverage and actionable research to PropThink Premium and Premium Plus subscribers.

Retrophin’s Busy Week: A Financing, a Drug Approval and a Valuable FDA Voucher

Just a day after Retrophin Inc. (NASDAQ:RTRX) announced a $100 million financing the U.

DEALS AND RUMORS OF DEALS DOMINATED THIS WEEK IN HEALTHCARE

This week was a busy one for biopharma BD teams. Finallized on Sunday, Valeant (VRX) will pay $158 per share for Salix Pharmaceuticals (SLXP) in an all-cash …

Investors Should be Paying Attention to Xencor

Xencor, Inc (NASDAQ:XNCR) priced an equity financing on Wednesday morning, selling 7.5 million shares of common stock at $14.

These Biotech IPO’s Just Don’t Stop

The latest in the onslaught of biotech initial public offerings, Spark Therapeutics (ONCE) priced at $23 on Thursday evening. Twelve hours later, the stock opened at …

QLT Inc. Left By Auxilium: Favorable Risk/Reward In Uncertain Market

Endo Health (NASDAQ:ENDP) and Auxilium Pharmaceuticals (NASDAQ:AUXL) finally came to terms in ongoing buyout negotiations, with ENDP handing over $2.6 billion ($33.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts